GSK-3β inhibitor 13

GSK-3β inhibitor 13 (compound 47) is an orally active and potent GSK-3β inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits GSK-3β and GSK-3α with IC50s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC50=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease[1].

Product Specifications

CAS Number

[2227316-74-5]

UNSPSC

12352005

Target

AAK1; GSK-3; Pim; PKC; Tau Protein

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/gsk-3β-inhibitor-13.html

Purity

99.74

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=NN2C1=NC(C3=CC=CC=C3)=C2)NC4=C(C=CN=C4)N5CCOC(C5)C

Molecular Formula

C23H22N6O2

Molecular Weight

414.46

References & Citations

[1]Hartz RA, et al. Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors. J Med Chem. 2023 Mar 23;66 (6) :4231-4252.